Treatment Timeline During the first two weeks, some patients notice immediate improvement in mobility due to reduced inflammation, while others experience gradual changes
First-of-its-kind Noom Psychosocial GLP-1 Report finds more than 90% of GLP-1 users say medication helped them adopt healthier habits, with reported benefits extending beyond weight to quality of life, joy, and metabolic health Princeton, NJ, May 5, 2026 Noom, the leading behavior change company, today announced that Charles Duhigg Pulitzer Prizewinning journalist and author of The Power of Habit, one of the best-selling and most influential books on human behavior of the last decade has joined the company as an advisor focused on maximizing the impact of GLP-1s as habit catalysts
J Biol Chem 264(17):98149819 Conflict of interest The author declares that he has no conflict of interest
Its important to consult with your healthcare provider before making any changes to your medication plan
Triple agonists add glucagon receptor activation, which: Increases resting energy expenditure by 8% to 12% (Jall et al., Diabetes Care 2024) Promotes hepatic fat oxidation and reduces steatosis May offset some of the lean mass loss seen with GLP-1 monotherapy (early signal, not yet confirmed in long-term trials) The weight loss ceiling for retatrutide appears to be 24% to 26% based on phase 3 data, though long-term real-world outcomes are not yet available
Iraqi J Vet Med